Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007583 | 0.83 | EGFR (0.38) | EGFRPIK3CGHSP90AA1CDK2 | |
| SCHEMBL3292267 | 0.76 | PIK3CG (0.47) | EGFRPIK3CGHSP90AA1 | |
| SCHEMBL316631 | 0.74 | PIK3CG (0.44) | EGFRPIK3CG | |
| SCHEMBL2467156 | 0.74 | ALDH1A1 (0.41) | EGFRPIK3CGCDK2 | |
| SCHEMBL29924424 | 0.74 | PIK3CG (0.37) | EGFRPIK3CG | |
| SCHEMBL4389242 | 0.74 | PIK3CG (0.37) | EGFRPIK3CG | |
| SCHEMBL30211632 | 0.74 | PIK3CG (0.37) | EGFRPIK3CG | |
| SCHEMBL2011723 | 0.74 | PIK3CG (0.37) | EGFRPIK3CG | |
| SCHEMBL316630 | 0.74 | PIK3CG (0.37) | EGFRPIK3CG | |
| SCHEMBL2629407 | 0.74 | PIK3CG (0.37) | EGFRPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102076690-A | Protein kinase inhibitors | VERTEX PHARMA | 2011-05-25 | — | — | CN | claimed |
| CN-115322209-B | Tri-fused ring compounds as DNA-PK inhibitors | 湖北理工学院 | 2023-06-20 | — | — | CN | disclosed |
| CN-115322209-A | Tricyclic compounds as DNA-PK inhibitors | 湖北理工学院 | 2022-11-11 | — | — | CN | disclosed |
| CN-110511226-A | Compound or its salt or solvate, its application and pharmaceutical composition | UNIV SOUTHWEST JIAOTONG | 2019-11-29 | — | — | CN | disclosed |
| US-9918934-B2 | Linker-based lecithin microemulsion delivery vehicles | ACOSTA ZARA EDGAR JOEL (CA) | 2018-03-20 | — | — | US | disclosed |
| EP-2120871-B2 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | ACOSTA-ZARA EDGAR JOEL (CA) | 2017-12-20 | — | — | EP | disclosed |
| EP-2120871-B1 | LINKER-BASED LECITHIN MICROEMULSION DELIVERY VEHICLES | ACOSTA-ZARA EDGAR JOEL (CA) | 2014-11-26 | — | — | EP | disclosed |
| CN-101484457-B | 4, 5-dihydro- [1,2,4] triazolo [4,3-f ] pteridines as protein kinase PLK1 inhibitors for the treatment of proliferative disorders | VERTEX PHARMA | 2014-09-03 | — | — | CN | disclosed |
| US-8394974-B2 | Process for producing optically active chromene oxide compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-03-12 | — | — | US | disclosed |
| US-7964623-B2 | Tricyclic benzopyrane compound | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2011-06-21 | — | — | US | disclosed |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY | 2007-03-01 | — | — | US | disclosed |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | 4 AZA BIOSCIENCE NV (BE) | 2007-02-08 | — | — | US | disclosed |
| US-7169778-B2 | Pteridinones as kinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1732929-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | Nissan Chemical Industries, Ltd. (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1673092-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA Bioscience nv (BE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005090357-A1 | TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005039587-A1 | HETEROCYCLE-SUBSTITUTED PTERIDINE DERIVATIVES AND THEIR USE IN THERAPY | 4 AZA BIOSCIENCE NV (BE) | 2005-05-06 | — | — | WO | disclosed |
| EP-1409487-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-04-21 | — | — | EP | disclosed |
| US-20030130286-A1 | Pteridinones as kinase inhibitors | DENNY WILLIAM ALEXANDER (NZ) | 2003-07-10 | — | — | US | disclosed |
| WO-2001019825-A1 | PTERIDINONES AS KINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130286-A1 | Pteridinones as kinase inhibitors | CCNI, CCNK, CDK2 | EGFR 128/4885PIK3CG 135/4885HSP90AA1 3897/4885 |
| US-20070049600-A1 | PTERIDINONES AS KINASE INHIBITORS | CCNI, CCNK, CDK2 | EGFR 70/4885PIK3CG 422/4885HSP90AA1 3794/4885 |
| US-20070032477-A1 | Pteridine derivatives useful for making pharmaceutical compositions | TPMT, TYMS, TNF | EGFR 3866/4885PIK3CG 1315/4885HSP90AA1 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.